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Abstract
Patent arterial duct (PAD) is a congenital heart abnormality defined as persistent patency in term
infants older than three months. Isolated PAD is found in around 1 in 2000 full term infants. A
higher prevalence is found in preterm infants, especially those with low birth weight. The female to
male ratio is 2:1. Most patients are asymptomatic when the duct is small. With a moderate-to-large
duct, a characteristic continuous heart murmur (loudest in the left upper chest or infraclavicular
area) is typical. The precordium may be hyperactive and peripheral pulses are bounding with a wide
pulse pressure. Tachycardia, exertional dyspnoea, laboured breathing, fatigue or poor growth are
common. Large shunts may lead to failure to thrive, recurrent infection of the upper respiratory
tract and congestive heart failure. In the majority of cases of PAD there is no identifiable cause.
Persistence of the duct is associated with chromosomal aberrations, asphyxia at birth, birth at high
altitude and congenital rubella. Occasional cases are associated with specific genetic defects
(trisomy 21 and 18, and the Rubinstein-Taybi and CHARGE syndromes). Familial occurrence of
PAD is uncommon and the usual mechanism of inheritance is considered to be polygenic with a
recurrence risk of 3%. Rare families with isolated PAD have been described in which the mode of
inheritance appears to be dominant or recessive. Familial incidence of PAD has also been linked to
Char syndrome, familial thoracic aortic aneurysm/dissection associated with patent arterial duct,
and familial patent arterial duct and bicuspid aortic valve associated with hand abnormalities.
Diagnosis is based on clinical examination and confirmed with transthoracic echocardiography.
Assessment of ductal blood flow can be made using colour flow mapping and pulsed wave Doppler.
Antenatal diagnosis is not possible, as PAD is a normal structure during antenatal life. Conditions
with signs and symptoms of pulmonary overcirculation secondary to a left-to-right shunt must be
excluded. Coronary, systemic and pulmonary arteriovenous fistula, peripheral pulmonary stenosis
and ventricular septal defect with aortic regurgitation and collateral vessels must be differentiated
from PAD on echocardiogram. In preterm infants with symptomatic heart failure secondary to
PAD, treatment may be achieved by surgical ligation or with medical therapy blocking prostaglandin
synthesis (indomethacin or ibuprofen). Transcatheter closure of the duct is usually indicated in
older children. PAD in preterm and low birth weight infants is associated with significant co-
morbidity and mortality due to haemodynamic instability. Asymptomatic patients with a small duct
have a normal vital prognosis but have a lifetime risk of endocarditis. Patients with moderate-to-
large ducts with significant haemodynamic alterations may develop irreversible changes to
pulmonary vascularity and pulmonary hypertension.
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Definition and diagnostic criteria
The arterial duct is an essential fetal structure and only
becomes abnormal if it remains open after the neonatal
period. Persistence of the arterial duct has been defined as
continued patency in term infants older than 3 months
[1]. It can be defined by combining both the clinical fea-
tures and anatomical measurements acquired from
echocardiogram as small, moderate or large and by con-
figuration on angiogram, as described by Krichenko et al.
[2].
Epidemiology
Isolated patent arterial duct is found in around 1 in 2000
full term infants, constituting nearly 10% of all congenital
heart disease [3] and is the second most common congen-
ital heart defect [4]. The overall incidence in infants born
prematurely is 8 per 1000 live births with extremely high
incidence of ductal patency in low birth weight infants
[1]. Siassi et al. [5] reported that the incidence of patent
arterial duct was 21% in a prospective study on 150 pre-
term infants with low birth weight. However, spontane-
ous delayed closure of the arterial duct occurred in 79% of
their patients who survived the immediate neonatal
period. The majority of reports show that there is a higher
incidence in females, with a female to male ratio of ~2:1.
Studies have revealed recurrence rates of between 1–5%
among siblings of individuals with isolated patent arterial
duct [6-10]. There are case reports which have shown
much higher recurrence rates in individual families, sug-
gesting different inheritance patterns in these families
[11]. The familial occurrence of patent arterial duct is
uncommon. An epidemiology paper from Carleton cover-
ing the period between 1941–58 found only 41 families
where the same cardiac defect occurred in two family
members and of these only 17 had patent arterial duct
[12].
Clinical description
Most patients are asymptomatic (when the duct is small).
In a moderate-to-large duct, the patency of the arterial
duct is recognised on detection of the characteristic con-
tinuous heart murmur. Often termed a "machinery mur-
mur", this is typically loudest at the left upper chest or
infraclavicular area. The precordium may be hyperactive
and peripheral pulses are bounding with a wide pulse
pressure. The patient may have tachycardia and in older
children there may be a history of exertional dyspnoea.
There may be history of prematurity, asphyxia, or mater-
nal rubella. The baby may have fast or laboured breathing,
become tired easily, or display poor growth. Large shunts
may lead to failure to thrive, recurrent infection of the
upper respiratory tract and congestive heart failure [1].
There is a subset of patients who have been found to have
a patent duct but remain asymptomatic and have no audi-
ble murmur, this group is often referred to as having a
'silent' duct.
In premature infants, there should be a high index of sus-
picion. Often ventilated infants with hyaline membrane
disease will improve followed by an inability to wean ven-
tilation or require increased support. There may be epi-
sodes of apnoea, bradycardia or general cardiovascular
instability. Physical examination may be similar to older
children with tachycardia, a continuous murmur and
bounding pulses however it is not uncommon for the
murmur to be only systolic.
In patients where a moderate-to-large patent duct has not
been previously diagnosed, irreversible pulmonary vascu-
lar changes may occur secondary to prolonged exposure
of high pulmonary flow and pressure. These changes
include arteriolar medial hypertrophy, intimal prolifera-
tion and fibrosis. In this group of patients when pulmo-
nary arterial pressure exceeds systemic pressure, the flow
across the duct is reversed and is right to left. This results
in the patient becoming cyanosed which may be differen-
tial with cyanosis and possibly clubbing seen in the feet
but not the fingers. The murmur may disappear with
accentuation of the second heart sound as a result of high
pulmonary pressure. These patients will have a progres-
sive reduction in their exercise capacity.
Aetiology
The arterial duct is the arterial connection between the
pulmonary artery and the aorta that shunts blood away
from the lungs during fetal life. In normal cardiovascular
embryological development the arterial duct is formed
from the sixth pair of embryonic arches. The distal portion
of the left sixth arch persists as the arterial duct, connect-
ing the left pulmonary artery with the left dorsal aorta
with regression of the right distal arch. This process is
completed by the 8th week of fetal life. The duct normally
constricts shortly after birth due to the postnatal drop in
circulating prostaglandin E2 levels, as well as the rise in
systemic oxygen tension, which induce a cytochrome
P450-dependent increase in endothelin-1 in ductal
smooth muscle cells [13]. Subsequent to this constriction,
the ductal endothelial cells detach, the subendothelial
region swells leading to the formation of subintimal cush-
ions, and the smooth muscle cells migrate to the duct
region, resulting in complete ductal closure and forma-
tion of the ductal ligament [14].
In a term infant with a patent arterial duct, the structure of
the ductal wall is abnormal. Histologically, the internal
elastic lamina of the arterial duct is generally intact and
the internal cushions are absent or less well formed than
usual [15]. In the premature infant, persistent patency of
the arterial duct is usually a result of hypoxia or immatu-
rity, with the duct usually having a normal structure [16].
In the majority of cases of patent arterial duct there is no
identifiable cause. These cases represent the influence ofOrphanet Journal of Rare Diseases 2009, 4:17 http://www.ojrd.com/content/4/1/17
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multifactorial inheritance [17]. Persistence of the duct is
associated with chromosomal aberrations, asphyxia at
birth, birth at high altitude, and congenital rubella [1]. It
has been suggested that there is a higher incidence in chil-
dren born to mothers with TT genotype of MTHFR C677T
locus involved in homocysteine metabolism [18],
although there are environmental influences contributing
to these findings.
Occasional cases are associated with specific genetic
defects. These include chromosomal defects, such as tri-
somy 21 and 18, deletion syndromes 4q-, 16p13.13
(Rubinstein-Taybi) and 9p- (CHARGE). Issekutz's epide-
miological study looking at infants diagnosed with
CHARGE syndrome in Canada demonstrated a higher
incidence of patent arterial duct in subgroup B, who
present with only three or fewer major criteria [19]. Famil-
ial patent arterial duct can be either isolated or part of a
syndrome.
Isolated familial patent arterial duct
• Autosomal dominant inheritance
Families with a high incidence of persistent patency of the
arterial duct have been reported by several researchers
[11,20-23]. In these families, the incidence of patent arte-
rial duct is higher than might be expected with a polygenic
mode of inheritance. In one report, there was a high fre-
quency of patent arterial ducts in three generations affect-
ing both sexes in the absence of consanguinity, highly
suggestive of an autosomal dominant mode of inherit-
ance [11].
￿ Autosomal recessive inheritance
Wei et al. described a family in which four out of six chil-
dren of the same family were affected with patent arterial
duct [24]. Their parents and grandparents were all free of
congenital heart disease. They suggested that autosomal
recessive inheritance might play a role, as other potential
causes (e.g. maternal rubella, maternal alcohol abuse, and
high altitude) could be excluded from this case.
Mani et al. found that patent arterial duct accounted for
15% of congenital heart disease in Iran, compared to 2%–
7% in the United States [25]. Moreover, parental consan-
guinity was significantly higher among patients with pat-
ent arterial duct (63%) than among the general Iranian
population (25%) or among control cases with tetralogy
of Fallot (30%). The recurrence of patent arterial duct
among siblings was 5%. A genome-wide analysis of link-
age in 21 unrelated consanguineous patent arterial duct
cases demonstrated a multipoint logarithm, with an odds
score of 6.27 in favour of linkage of patent arterial duct to
a 3-centimorgan interval of chromosome 12q24 with
53% of kindred's linked. Together, these findings suggest
that there is a recessive component involved in patent
arterial duct and implicate a single locus in one third or
more of all patent arterial duct cases in Iran. They further
suggest a role for this locus in patent arterial duct world-
wide. The authors suggest that persistent patency of the
arterial duct is commonly a recessive disease with incom-
plete penetrance.
Familial patent arterial duct as part of a syndrome
￿ Char syndrome
Char syndrome is an autosomal dominant condition
comprising ptosis, low-set ears, short philtrum and 'duck-
bill' lips, patent arterial duct, a single fifth finger flexion
crease with two fifth finger phalanges and mild learning
difficulties. Other features described include a broad fore-
head, flared eyebrows, mild hypertelorism, flat midface
and strabismus. First described by Char in 1978, this syn-
drome has subsequently been reported by several subse-
quent investigators [26-29]. The facial findings were less
pronounced in older relatives and a change in phenotype
with age has been reported by different researchers
[26,28]. Additionally, the phenotype has been reported to
vary, even within families, presumably due to different
mutations in the same gene. The patent arterial duct in
five multigenerational families studied has been of varia-
ble penetrance.
Char syndrome has been mapped to a narrow region of
chromosome 6p12-p21 [29]. Further studies have shown
that Char syndrome is caused by defects in TFAP2B,
encoding a neural crest-related transcription factor (also
known as AP-2β). The TFAP2 genes play an important role
in retinoic acid-induced differentiation, particularly in
cells derived from the neuroectoderm. Thus, it appears
that the patent arterial duct in Char syndrome is likely a
result of abnormal neural crest development [30].
￿ Familial thoracic aortic aneurysm/dissection (TAA/AD) with patent 
arterial duct
Khau Van Kien et al. described a single large three-genera-
tional French family with a vascular syndrome that associ-
ates TAA/AD with patent arterial duct [31]. Genetic
analysis of this family identified a locus at chromosome
16p12.2-p13.13 with aortic stiffness as an early hallmark
of the disease [32]. Mutations in the MYH11 gene were
eventually identified, which encodes the smooth muscle
myosin heavy chains, however this is only thought to be
involved in rare instances in sporadic instances of patent
duct [33]. The mode of inheritance appeared to be auto-
somal dominant and genetic linkage analysis excluded
involvement of the previously described loci associated
with syndromic and non-syndromic familial TAA/AD,
Char syndrome and recessive patent arterial duct. Similar
suggestions were also made by Glancy et al. and Telen et
al. [34,35]. The former also described a single family in
whom TAA/AD and patent arterial duct occurred in threeOrphanet Journal of Rare Diseases 2009, 4:17 http://www.ojrd.com/content/4/1/17
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generations with apparent autosomal dominant inherit-
ance. In all these studies no other features of typical con-
nective disorders were observed.
￿ Familial patent arterial duct and bicuspid aortic valve with hand 
anomalies
A novel inherited syndrome has recently been described
comprising variable cardiovascular defects (patent arterial
duct, bicuspid aortic valve, pseudocoarctation of the
aorta), hand anomalies (consisting of 5th metacarpal
hypoplasia of varying degree), and generalised brachydac-
tyly. Linkage analysis with this moderate-sized kindred
using polymorphic DNA markers from the Char syn-
drome locus excluded the possibility that this family was
inheriting an allelic variant of Char syndrome. Inspection
of the pedigree favoured inheritance by a dominant mech-
anism. However, X-linked dominance could not be
excluded. Penetrance appeared to be complete, but there
was variability in the cardiac and hand phenotypes [36].
Diagnostic methods
Diagnosis is usually possible based on clinical examina-
tion. The confirmation of a patent arterial duct is made
with transthoracic echocardiography. In the majority of
cases, cross sectional echocardiography can accurately
define the presence and characteristics of a patent arterial
duct. The most commonly employed views are left par-
asternal, high left parasternal, suprasternal and short axis
views [37]. The arterial duct can be measured on standard
two dimensional views in the high parasternal position
where it forms a 'three-legged' appearance with the pul-
monary arteries. Assessment of ductal blood flow can be
made using colour flow mapping (Figure 1) and pulsed
wave Doppler. Particular attention should be paid to the
direction and flow pattern to gain information relating to
restrictive flow pattern, shunt assessment and an indirect
indication of pulmonary arterial pressure. However, it
may be difficult to image the ductus in older patients,
transoesophageal echocardiography with colour flow
mapping has shown increased sensitivity in adolescent
and adult patients [38,39]. As pulmonary vascular resist-
ance falls after birth, the left to right shunt increases, lead-
ing to increased pulmonary over circulation and increased
pulmonary venous return. As a consequence, there is left
atrial and left ventricular volume loading, seen as enlarge-
ment of the left atrium and ventricle on apical four cham-
ber and long axis views. As a result of ventricular
enlargement, there may be a degree of mitral regurgita-
tion. The degree of volume loading can be approximated
using the left atrium:aortic root ratio, a significant shunt
being considered one that gives a value of > 1.3 [37,40].
This is best assessed using the m-mode in a standard long
axis view.
Diagnostic cardiac catheterisation with angiography is
rarely necessitated in patients with typical clinical and
echocardiographic findings. Predominately catheterisa-
tion is limited to transcatheter therapies for occlusion of
the duct. In this setting, ductal anatomy is usually defined
with aortography (Figure 2). The configuration of the duc-
Echocardiography, a high parasternal long axis view demonstrating a large patent duct (PDA) Figure 1
Echocardiography, a high parasternal long axis view demonstrating a large patent duct (PDA). Colour flow dem-
onstrates shunting from 'left to right', from the descending aorta (DAO) to the pulmonary arteries (MPA).Orphanet Journal of Rare Diseases 2009, 4:17 http://www.ojrd.com/content/4/1/17
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tus as demonstrated on the lateral angiogram can be clas-
sified as described by Krichenko et al. [2]. The Type A or
conical duct has a well defined aortic ampulla and con-
striction near the pulmonary artery end. Type B is a large
duct with window-like structure, which is very short in
length. Type C is a tubular duct without any constriction.
Type D is the complex duct with multiple constrictions
and the type E or elongated duct with constriction remote
from the edge of the trachea as viewed on lateral angiog-
raphy (Figure 3). This classification system allows the
interventionalist to assess the size and configuration of
the duct and select the most suitable occlusion device.
Genetic counselling
There have been significant advances in the understand-
ing and identification of genetic causes of congenital heart
disease in the last decade and continues to be a field
which is changing rapidly [41]. The recognition of sub-
groups of patients with a stronger genetic component to
the aetiology of patent arterial duct is important for the
counselling of couples with concerns regarding the risks
of recurrence. The recognition of familial causes of patent
arterial duct stresses the importance of a full family his-
tory and of careful examination of the facial features
before estimating recurrence risk for patent arterial duct.
Lateral angiogram demonstrating a large tubular type duct  (type C) with aortic (AO) to pulmonary flow (MPA) Figure 2
Lateral angiogram demonstrating a large tubular 
type duct (type C) with aortic (AO) to pulmonary 
flow (MPA). The catheter can be seen entering the MPA 
from the right ventricle, a second pigtail catheter is posi-
tioned in the descending aorta from which contrast is deliv-
ered.
Diagrammatic representation of the configuration of the duc- tus as demonstrated on the lateral angiogram can be classi- fied as described by Krichenko Figure 3
Diagrammatic representation of the configuration of 
the ductus as demonstrated on the lateral angiogram 
can be classified as described by Krichenko. Type A or 
conical duct with well defined aortic ampulla and constriction 
near the pulmonary artery end. Type B is a large duct with 
window like structure which is very short in length. Type C 
is a tubular duct without any constriction. Type D is the 
complex duct with multiple constrictions and the type E or 
elongated duct with constriction remote from the edge of 
the trachea as viewed on lateral angiography (figure adapted 
from Amplatzer™ manufacturer information).Orphanet Journal of Rare Diseases 2009, 4:17 http://www.ojrd.com/content/4/1/17
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Antenatal diagnosis
Antenatal diagnosis of patent arterial duct is not possible
as it is a normal structure during antenatal life. At present,
there are no antenatal genetic investigations that can reli-
ably predict the patency of the arterial duct in postnatal
life.
Differential diagnosis
Conditions in which there are signs and symptoms of pul-
monary over circulation secondary to a left to right shunt
must be excluded. Other conditions may also present with
a continuous murmur and bounding pulses and differen-
tiation from an arterial duct must be made on echocardi-
ogram. These include: coronary, systemic and pulmonary
arteriovenous fistula, collateral vessels, peripheral pulmo-
nary stenosis and ventricular septal defect with aortic
regurgitation [42].
Management
Preterm infants with symptomatic heart failure secondary
to persistent patency of the arterial duct may be treated by
surgical ligation or medically with conservative manage-
ment and indomethacin or ibuprofen. Medical interven-
tion is usually the treatment of choice due to the risks
involved with surgical ligation. Initial conservative man-
agement involves fluid restriction and diuretic therapy
with optimisation of calorie intake and ventilator sup-
port. These actions will not aid ductal closure but can
improve respiratory physiology and symptoms in the
short term. Indomethacin and ibuprofen act as inhibitors
of prostaglandin forming cyclo-oxygenase (COX)
enzymes. No statistical difference has been demonstrated
between ibuprofen and indomethacin in their effective-
ness in closing a patent duct [43]. Indomethacin has
greater inhibition of COX-1 receptors and consequently
greater vasoconstrictive effects with ibuprofen offering rel-
atively less inhibition. Both drugs have potentially serious
adverse effects with indomethacin associated with renal
dysfunction, necrotising enterocolitis and impairment of
cerebral blood flow but potentially protective effect
against intraventricular haemorrhage [44,45]. It has been
suggested that ibuprofen may increase the risk of chronic
lung disease and pulmonary hypertension has been
described when ibuprofen was given prophylactically
[46]. Both drugs are protein bound and so in the neonate
can potentially compete with bilirubin for albumin bind-
ing sites, resulting in an increase in free bilirubin and the
Echocardiogram following closure of patent duct with an  Amplatzer ductal occluder II™ Figure 5
Echocardiogram following closure of patent duct 
with an Amplatzer ductal occluder II™. This image is 
taken from the same patient as figure 3c. This high paraster-
nal long axis clearly shows the device fixed in the duct 
between left pulmonary artery and descending aorta.
a) Lateral angiogram showing a Cook™ flipper coil with complete occlusion of the duct on angiography; b) The same patient as  demonstrated in figure 2 that has been successfully closed using an Amplatzer ductal occluder™ (ADO); c) Successful closure  of the patent duct demonstrated in figure 1 with an Amplatzer ductal occluder II ™ (ADO II) Figure 4
a) Lateral angiogram showing a Cook™ flipper coil with complete occlusion of the duct on angiography; b) 
The same patient as demonstrated in figure 2 that has been successfully closed using an Amplatzer ductal 
occluder™ (ADO); c) Successful closure of the patent duct demonstrated in figure 1 with an Amplatzer ductal 
occluder II ™ (ADO II).Orphanet Journal of Rare Diseases 2009, 4:17 http://www.ojrd.com/content/4/1/17
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risk of bilirubin encephalopathy [47]. Timing of interven-
tion and dosage of pharmacologic treatment remains a
debated topic. Indomethacin can be given as either a short
course of three doses 12 hourly or as a long course of six
doses 24 hourly. There is no difference in ductal closure
rates between the two but the longer course has a lower
incidence of ductal reopening [48,49]. It is known that the
optimal time for treatment is less than a week of age, how-
ever this must be balanced against treating infants and
exposing them to potential side effects when the duct
would have closed spontaneously. Current trends would
support treatment within the first week of life and in
symptomatic older infants but accepting that treatment
failure and ductal reopening may well occur in the older
age infants [50].
A number of infants will either not be suitable or fail med-
ical management. These include infants with renal impair-
ment, gastrointestinal pathology including previous
necrotising enterocolitis and patients with platelet dys-
function. In such cases, surgical division and ligation is
indicated for closure of a significant arterial duct. This is
performed via a thoracotomy and whilst high closure rates
and low mortality are reported there may be significant
morbidity. These include bleeding, pneumothorax, chy-
lothorax, infection, haemodynamic instability and tho-
racic scoliosis. A minimally invasive surgical approach
employing video-assisted thoracic surgery (VATS) has
shown early results comparable to thoracotomy including
premature and low birth weight infants [51,52].
In children outside of this age group, the management
decisions are based on the control of symptomatic pulmo-
nary over circulation and the lifetime risk of endocarditis.
Transcatheter closure of the duct is usually offered to all
children outside of the neonatal period. There have been
several studies reporting excellent results with low com-
plication rates for a variety of occluders (Figure 4a–c, 5)
[53-56]. Surgical ligation remains an option for those
unsuitable for transcatheter closure. This is now rare with
the range of occluders developed but may include very
large ducts where adequate anchorage of the occluder is
not possible.
The best management for the 'silent' duct remains debat-
able with many centres electing not to close either surgi-
cally or via catheter techniques. The risk of endocarditis is
low, although studies have reported an increase in the
incidence in these patients [57]. This has prompted some
centres to offer elective closure of the patent duct to all
patients [58].
Prognosis
The prognosis for the untreated patent arterial duct
depends largely on the size of the duct and the degree of
left to right shunt and pulmonary over circulation. In pre-
term and low birth weight infants a patent duct is associ-
ated with significant co-morbidity and mortality due to
haemodynamic instability. These include pulmonary
oedema and haemorrhage, bronchopulmonary dysplasia,
intraventricular haemorrhage necrotizing enterocolitis as
well as congestive cardiac failure. Patients with a small
duct may exhibit no symptoms and have no haemody-
namic impairment, these patients have a normal progno-
sis but do have a lifetime risk of endocarditis. Those
patients with moderate-to-large ducts with significant
haemodynamic changes may present with evidence of
congestive cardiac failure or in the long term may develop
irreversible changes to pulmonary vascularity and pulmo-
nary hypertension [59]. Patients presenting with signs of
cardiac failure would usually be offered either transcathe-
ter or surgical closure of the duct. Irreversible pulmonary
vascular changes or Eisenmenger's syndrome as a result of
duct is fortunately rare, but in such cases treatment is
largely supportive.
For patients who undergo transcatheter closure the imme-
diate occlusion rates are in excess of 90% and immediate
complication rates are low [53-56,60,61]. There is poten-
tial for left pulmonary artery and descending aortic
obstruction in patients who are of low weight with a large
duct requiring a relatively large occluder for closure. How-
ever, this is rare and normally resolves with age as vessel
calibre naturally increases.
Surgical ligation and division of the arterial duct has been
shown to have excellent results although is more invasive
than transcatheter techniques. It remains an important
treatment option for arterial ducts which are unsuitable
for transcatheter closure and in premature infants in
which medical management has failed. Occlusion rates
are in excess of 95% with mortality figures 1–2% [62].
Once the patent duct has been occluded, the long term
risk of endocarditis returns to levels for the overall normal
population risk. Haemodynamic changes are removed
with resolution of a normal circulation.
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